<DOC>
	<DOC>NCT02959944</DOC>
	<brief_summary>To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.</brief_summary>
	<brief_title>Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>New onset moderate or severe cGVHD as defined by the 2014 NIH Consensus Development Project Criteria Need for systemic treatment with corticosteroids for cGVHD No previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP]) May be receiving other immunosuppressants for the prophylaxis or treatment of acute GVHD but the doses of these medications must have been stable for at least 2 weeks prior to Screening Age ≥12 years old Karnofsky or Lansky (subjects &lt;16 years) performance status ≥60 Received any previous systemic treatment for cGVHD Inability to begin a prednisone dose ≥0.5 mg/kg/d for the treatment of cGVHD Any uncontrolled infection or active infection requiring ongoing systemic treatment Progressive underlying malignant disease or any posttransplant lymphoproliferative disease Known bleeding disorders Active hepatitis C virus (HCV) or hepatitis B virus (HBV)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic graft versus host disease</keyword>
	<keyword>PCYC1140</keyword>
	<keyword>PCYC1140IM</keyword>
	<keyword>1140</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>GVHD</keyword>
	<keyword>Steroid dependent</keyword>
	<keyword>refractory</keyword>
	<keyword>chronic</keyword>
	<keyword>PCI32765</keyword>
	<keyword>IMBRUVICA</keyword>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>immunology</keyword>
	<keyword>new onset graft versus host disease</keyword>
	<keyword>INTEGRATE</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>prednisone</keyword>
</DOC>